Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Cara Therapeutics, Inc.    CARA

CARA THERAPEUTICS, INC.

(CARA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Cara: 4Q Earnings Snapshot

02/25/2021 | 05:03pm EDT

STAMFORD, Conn. (AP) _ Cara Therapeutics Inc. (CARA) on Thursday reported fourth-quarter net income of $78.9 million, after reporting a loss in the same period a year earlier.

On a per-share basis, the Stamford, Connecticut-based company said it had net income of $1.59.

The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 53 cents per share.

The biotechnology company posted revenue of $112.1 million in the period, also exceeding Street forecasts. Three analysts surveyed by Zacks expected $6.6 million.

For the year, the company reported net income of $8.4 million, or 18 cents per share, swinging to a profit in the period. Revenue was reported as $135.1 million.

Cara shares have risen 27% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $19.26, an increase of 20% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CARA at https://www.zacks.com/ap/CARA

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about CARA THERAPEUTICS, INC.
04/07Cara Therapeutics to Present at the 20th Annual Needham Healthcare Conference
GL
04/07CARA THERAPEUTICS  : April 2021 Investor Fact Sheet
PU
04/07CARA THERAPEUTICS  : 2021 R&D Day Presentation
PU
04/07CARA THERAPEUTICS  : March 2021 Corporate Presentation
PU
04/06AFTER HOURS WATCH LIST SCORECARD : Ilmn, cara, uctt
MT
04/06Illumina, Cara Therapeutics rise; Greenbrier, Paychex fall
AQ
04/06SECTOR UPDATE : Health Care Stocks Fading Late
MT
04/06SECTOR UPDATE : Health Care Stocks Largely Staying on Positive Ground
MT
04/06Wall Street Inches Lower Pre-Bell, Consolidating After Record Rises
MT
04/05MT NEWSWIRES AFTER HOURS WATCH LIST : Ilmn, cara, uctt
MT
More news
Financials (USD)
Sales 2021 31,3 M - -
Net income 2021 -96,6 M - -
Net Debt 2021 - - -
P/E ratio 2021 -15,3x
Yield 2021 -
Capitalization 1 456 M 1 456 M -
Capi. / Sales 2021 46,5x
Capi. / Sales 2022 14,8x
Nbr of Employees 80
Free-Float 83,8%
Chart CARA THERAPEUTICS, INC.
Duration : Period :
Cara Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 35,13 $
Last Close Price 29,19 $
Spread / Highest target 61,0%
Spread / Average Target 20,3%
Spread / Lowest Target -28,1%
EPS Revisions
Managers and Directors
NameTitle
Derek T. Chalmers President, Chief Executive Officer & Director
Thomas Reilly Chief Financial & Accounting Officer
Frèdèrique Menzaghi Chief Scientific Officer, Senior VP-R&D
Joana Goncalves Chief Medical Officer
Scott M. Terrillion Secretary & Chief Compliance Officer
Sector and Competitors
1st jan.Capitalization (M$)
CARA THERAPEUTICS, INC.92.93%1 456
GILEAD SCIENCES, INC.11.60%81 977
VERTEX PHARMACEUTICALS-9.73%55 220
WUXI APPTEC CO., LTD.8.52%51 947
REGENERON PHARMACEUTICALS-1.40%49 486
BIONTECH SE49.83%29 499